Check out our comprehensive educational activities here

How does the concept of measurable residual disease (MRD) apply to therapy today and moving forward?

In this activity, Dr. Stein describes why MRD negativity is a goal of therapy and how to achieve it in certain patients.

Published on August 11, 2021 in Treatment

How does maintenance therapy fit into the framework of AML treatment?

In AML, the role of maintenance therapy has been unclear. In this activity, Dr. Stein reviews data from the QUAZAR study and which patients with AML may benefit from this treatment.

Published on August 2, 2021 in Treatment

A Case Study in Secondary AML: Best Practice for Treatment Selection

In this activity, Dr. Lancet discusses choice of therapy for a patient who presents with secondary AML.

This activity is supported by educational grants from Actinium Pharmaceuticals, Bristol-Myers Squibb, and Jazz Pharmaceuticals.

Published on January 20, 2021 in Treatment

Is it possible to deliver liposomal daunorubicin and cytarabine on an outpatient basis?

In this activity, Dr. Eunice Wang explains the adverse events associated with liposomal cytarabine and daunorubicin and how to manage them on an outpatient basis.

Published on December 7, 2020 in Treatment

What are the key factors you must take into consideration in determining upfront treatment for patients with high-risk, secondary AML?

Dr. Wang describes how she determines upfront therapy for a patient with newly diagnosed secondary AML.

Published on November 30, 2020 in Treatment